In preclinical models of poorly immunogenic melanoma and prostate cancer, the combination of anti-CTLA-4 and granulocyte/macrophage colony-stimulating factor (GM-CSF)-expressing vaccine had significant synergistic effects in eradicating tumors and eliciting an immune response dependent on increased CD8+ T cells [158,159]. Here, CTLA4 is linked to prostate cancer.